Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin

Pharmacology and Therapeutics

Volumn 151, Issue , 2015, Pages 32-40

  Collino, Massimo ^a   Thiemermann, Christoph ^b   Cerami, Anthony ^c   Brines, Michael ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ARAIM PHARMACEUTICALS   (United States)

Author keywords

ARA 290; Erythropoietin; Innate repair receptor; Pyroglutamate helix B surface protein; common receptor

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PLACEBO; PROTECTIVE AGENT; PYROGLUTAMATE HELIX B SURFACE PROTEIN; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG; ISOPROTEIN; OLIGOPEPTIDE; PYROGLUTAMATE HELIX B SURFACE PEPTIDE;

ANEMIA; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DRUG HALF LIFE; DRUG POTENCY; ERYTHROPOIESIS; HUMAN; INNATE IMMUNITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ENGINEERING; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE REPAIR; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM;

ANIMALS; ERYTHROPOIETIN; HUMANS; IMMUNITY, INNATE; OLIGOPEPTIDES; PROTECTIVE AGENTS; PROTEIN ISOFORMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ERYTHROPOIETIN;

EID: 84930089116     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.02.005     Document Type: Review

References (96)

1. M. Aapro, W. Jelkmann, S.N. Constantinescu, and B. Leyland-Jones Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer Br J Cancer 106 7 2012 1249 1258
2. I. Ahmet, H.J. Tae, M. Brines, A. Cerami, E.G. Lakatta, and M.I. Talan Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy J Pharmacol Exp Ther 345 3 2013 446 456
3. I. Ahmet, H.J. Tae, M. Juhaszova, D.R. Riordon, K.R. Boheler, and S.J. Sollott A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage Mol Med 17 3-4 2011 194 200
4. P. Alia, C. Villabona, O. Gimenez, E. Sospedra, J. Soler, and M.A. Navarro Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers Clin Endocrinol (Oxf) 65 3 2006 346 351
5. A. Anagnostou, E.S. Lee, N. Kessimian, R. Levinson, and M. Steiner Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells Proc Natl Acad Sci U S A 87 15 1990 5978 5982
6. L. Barbera, and G. Thomas Erythropoiesis stimulating agents, thrombosis and cancer Radiother Oncol 95 3 2010 269 276
7. Y. Bennis, G. Sarlon-Bartoli, B. Guillet, L. Lucas, L. Pellegrini, and L. Velly Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential J Thromb Haemost 10 9 2012 1914 1928
8. M. Bernaudin, A.S. Nedelec, D. Divoux, E.T. MacKenzie, E. Petit, and P. Schumann-Bard Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain J Cereb Blood Flow Metab 22 4 2002 393 403
9. S. Bohr, S.J. Patel, K. Shen, A.G. Vitalo, M. Brines, and A. Cerami Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns Proc Natl Acad Sci U S A 110 9 2013 3513 3518
10. S. Bohr, S.J. Patel, R. Vasko, K. Shen, A. Iracheta-Vellve, and J. Lee Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells J Mol Med (Berl) 93 2 2015 199 210
11. M. Brines The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors Blood Purif 29 2 2010 86 92
12. M. Brines, and A. Cerami Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response J Intern Med 264 5 2008 405 432
13. M. Brines, and A. Cerami The receptor that tames the innate immune response Mol Med 18 1 2012 486 496
14. M. Brines, and A. Cerami Erythropoietin and engineered innate repair activators Methods Mol Biol 982 2013 1 11
15. M. Brines, A.N. Dunne, M. Van Velzen, P.L. Proto, C.G. Ostenson, and R.I. Kirk ARA 290, a non-erythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes Mol Med 2014 10.2119/molmed.2014.00215 (Epub ahead of print)
16. M. Brines, G. Grasso, F. Fiordaliso, A. Sfacteria, P. Ghezzi, and M. Fratelli Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor Proc Natl Acad Sci U S A 101 41 2004 14907 14912
17. M. Brines, N.S. Patel, P. Villa, C. Brines, T. Mennini, and M. De Paola Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin Proc Natl Acad Sci U S A 105 31 2008 10925 10930
18. R. Burcelin, W. Dolci, and B. Thorens Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1 Metabolism 48 2 1999 252 258
19. L. Calvillo, R. Latini, J. Kajstura, A. Leri, P. Anversa, and P. Ghezzi Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci U S A 100 8 2003 4802 4806
20. M. Castro, V.O. Nikolaev, D. Palm, M.J. Lohse, and J.P. Vilardaga Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism Proc Natl Acad Sci U S A 102 44 2005 16084 16089
21. V. Cernaro, A. Lacquaniti, R. Lupica, A. Buemi, D. Trimboli, and G. Giorgianni Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein Med Res Rev 34 1 2014 77 105
22. S. Chattong, J. Tanamai, P. Kiatsomchai, M. Nakatsu, A. Sereemaspun, and N. Pimpha Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production Br J Pharmacol 168 1 2013 189 199
23. H. Chen, B. Luo, X. Yang, J. Xiong, Z. Liu, and M. Jiang Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat J Neuroimmunol 268 1-2 2014 64 70
24. Z.Z. Chong, J.Q. Kang, and K. Maiese Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades J Cereb Blood Flow Metab 22 5 2002 503 514
25. S.M. Coldewey, A.I. Khan, A. Kapoor, M. Collino, M. Rogazzo, and M. Brines Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the beta-common receptor Kidney Int 84 3 2013 482 490
26. P. Colella, C. Iodice, U. Di Vicino, I. Annunziata, E.M. Surace, and A. Auricchio Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration Hum Mol Genet 20 11 2011 2251 2262
27. M. Collino, E. Benetti, M. Rogazzo, F. Chiazza, R. Mastrocola, and D. Nigro A nonerythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice Br J Pharmacol 171 24 2014 5802 5815
28. M. Collino, M. Rogazzo, A. Pini, E. Benetti, A.C. Rosa, and F. Chiazza Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury J Cell Mol Med 17 11 2013 1494 1505
29. H.L. Corwin, A. Gettinger, T.C. Fabian, A. May, R.G. Pearl, and S. Heard Efficacy and safety of epoetin alfa in critically ill patients N Engl J Med 357 10 2007 965 976
30. P. Cravedi, J. Manrique, K.E. Hanlon, J. Reid-Adam, J. Brody, and P. Prathuangsuk Immunosuppressive effects of erythropoietin on human alloreactive T cells J Am Soc Nephrol 25 9 2014 2003 2015
31. A. Dahan, A. Dunne, M. Swartjes, PL. Proto, L. Heij, O. Vogels, M. van Velzen, E. Sarton, M. Niesters, MR. Tannemaat, A. Cerami, and M. Brines ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density Molecular medicine 19 2013 334 345
32. H. Ehrenreich, M. Hasselblatt, C. Dembowski, L. Cepek, P. Lewczuk, and M. Stiefel Erythropoietin therapy for acute stroke is both safe and beneficial Mol Med 8 8 2002 495 505
33. H. Ehrenreich, K. Weissenborn, H. Prange, D. Schneider, C. Weimar, and K. Wartenberg Recombinant human erythropoietin in the treatment of acute ischemic stroke Stroke 40 12 2009 e647 e656
34. Z.H. Endre, R.J. Walker, J.W. Pickering, G.M. Shaw, C.M. Frampton, and S.J. Henderson Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial) Kidney Int 77 11 2010 1020 1030
35. S. Erbayraktar, G. Grasso, A. Sfacteria, Q.W. Xie, T. Coleman, and M. Kreilgaard Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo Proc Natl Acad Sci U S A 100 11 2003 6741 6746
36. L. Heij, M. Niesters, M. Swartjes, E. Hoitsma, M. Drent, and A. Dunne Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study Mol Med 18 2012 1430 1436
37. B.B. Heinisch, B. Vcelar, S. Kapiotis, A. Blann, M. Wolzt, and J.M. Siller-Matula The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers Platelets 23 5 2012 352 358
38. H. Hui, L. Farilla, P. Merkel, and R. Perfetti The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects Eur J Endocrinol 146 6 2002 863 869
39. N. Imai, M. Higuchi, A. Kawamura, K. Tomonoh, M. Oh-Eda, and M. Fujiwara Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro Eur J Biochem 194 2 1990 457 462
40. D. Joshi, D. Abraham, X. Shiwen, D. Baker, and J. Tsui Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia J Vasc Surg 60 1 2014 191 201 (201.e191-192)
41. A.L. Kazim, and M.Z. Atassi Antibody combining sites can be mimicked synthetically. Surface-simulation synthesis of the phosphorylcholine-combining site of myeloma protein M-603 Biochem J 187 3 1980 661 666
42. A.I. Khan, S.M. Coldewey, N.S. Patel, M. Rogazzo, M. Collino, and M.M. Yaqoob Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor Dis Model Mech 6 4 2013 1021 1030
43. E. Khedr, M. El-Sharkawy, S. Abdulwahab, E.N. Eldin, M. Ali, and A. Youssif Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients Hemodial Int 13 3 2009 340 346
44. H. Kitamura, Y. Isaka, Y. Takabatake, R. Imamura, C. Suzuki, and S. Takahara Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model Nephrol Dial Transplant 23 5 2008 1521 1528
45. Y. Konishi, D.H. Chui, H. Hirose, T. Kunishita, and T. Tabira Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo Brain Res 609 1-2 1993 29 35
46. W. Krzyzanski, and E. Wyska Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers Naunyn Schmiedebergs Arch Pharmacol 377 4-6 2008 637 645
47. J.G. Lehoux, A. Fleury, and L. Ducharme The acute and chronic effects of adrenocorticotropin on the levels of messenger ribonucleic acid and protein of steroidogenic enzymes in rat adrenal in vivo Endocrinology 139 9 1998 3913 3922
48. M. Leist, P. Ghezzi, G. Grasso, R. Bianchi, P. Villa, and M. Fratelli Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 5681 2004 239 242
49. Y. Liu, B. Luo, F. Han, X. Li, J. Xiong, and M. Jiang Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection PLoS One 9 3 2014 e90942
50. A. Loesch, H. Tang, M.A. Cotter, and N.E. Cameron Sciatic nerve of diabetic rat treated with epoetin delta: effects on C-fibers and blood vessels including pericytes Angiology 61 7 2010 651 668
51. S. Masuda, M. Nagao, K. Takahata, Y. Konishi, F. Gallyas Jr., and T. Tabira Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells J Biol Chem 268 15 1993 11208 11216
52. S. Masuda, M. Okano, K. Yamagishi, M. Nagao, M. Ueda, and R. Sasaki A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes J Biol Chem 269 30 1994 19488 19493
53. K.L. McGraw, G.M. Fuhler, J.O. Johnson, J.A. Clark, G.C. Caceres, and L. Sokol Erythropoietin receptor signaling is membrane raft dependent PLoS One 7 4 2012 e34477
54. C.M. McVicar, R. Hamilton, L.M. Colhoun, T.A. Gardiner, M. Brines, and A. Cerami Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy Diabetes 60 11 2011 2995 3005
55. J.M. Murphy, and I.G. Young IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor Vitam Horm 74 2006 1 30
56. M. Niesters, M. Swartjes, L. Heij, M. Brines, A. Cerami, and A. Dunne The erythropoietin-analogue ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain Exp Opin Orphan Drugs 1 2013 77 87
57. Niesters M, Swartjes M, Heij L, Brines M, Cerami A, Dunne A, et al. The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain Vol. 1, pp 77-87: Expert Opinion in Orphan Drug.
58. N. Nogawa-Kosaka, T. Hirose, N. Kosaka, Y. Aizawa, K. Nagasawa, and N. Uehara Structural and biological properties of erythropoietin in Xenopus laevis Exp Hematol 38 5 2010 363 372
59. I. Ott, S. Schulz, J. Mehilli, S. Fichtner, M. Hadamitzky, and K. Hoppe Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial Circ Cardiovasc Interv 3 5 2010 408 413
60. T. Ozawa, K. Toba, H. Suzuki, K. Kato, Y. Iso, and Y. Akutsu Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study Circ J 74 7 2010 1415 1423
61. A. Palazon, A.W. Goldrath, V. Nizet, and R.S. Johnson HIF transcription factors, inflammation, and immunity Immunity 41 4 2014 518 528
62. N.S. Patel, M. Collino, M.M. Yaqoob, and C. Thiemermann Erythropoietin in the intensive care unit: beyond treatment of anemia Ann Intensive Care 1 2011 40
63. N.S. Patel, H.L. Kerr-Peterson, M. Brines, M. Collino, M. Rogazzo, and R. Fantozzi Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury Mol Med 18 2012 719 727
64. N.S. Patel, K.K. Nandra, M. Brines, M. Collino, W.F. Wong, and A. Kapoor A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock Mol Med 17 9-10 2011 883 892
65. K. Polgárová, P. Lüthje, A. Cerami, and A. Brauner The erythropoietin analogue ARA290 modulates the innate immune response and reduces Escherichia coli invasion into urothelial cells FEMS Immunol Med Microbiol 62 2 2011 190 196
66. E. Porpiglia, D. Hidalgo, M. Koulnis, A.R. Tzafriri, and M. Socolovsky Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities PLoS Biol 10 8 2012 e1001383
67. K.G. Pulman, M. Smith, M. Mengozzi, P. Ghezzi, and A. Dilley The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model Neuroscience 233 2013 174 183
68. C.S. Robertson, L. Cherian, M. Shah, R. Garcia, J.C. Navarro, and R.J. Grill Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock J Neurotrauma 29 6 2012 1156 1166
69. C.S. Robertson, H.J. Hannay, J.M. Yamal, S. Gopinath, J.C. Goodman, and B.C. Tilley Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial JAMA 312 1 2014 36 47
70. M.R. Rubin, and J.P. Bilezikian Parathyroid hormone as an anabolic skeletal therapy Drugs 65 17 2005 2481 2498
71. E. Saulle, R. Riccioni, S. Coppola, I. Parolini, D. Diverio, and V. Riti Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation Br J Haematol 145 3 2009 399 411
72. L. Sautina, Y. Sautin, E. Beem, Z. Zhou, A. Schuler, and J. Brennan Induction of nitric oxide by erythropoietin is mediated by the {beta} common receptor and requires interaction with VEGF receptor 2 Blood 115 4 2010 896 905
73. R.E. Schmidt, D. Feng, Q. Wang, K.G. Green, L.L. Snipes, and M. Yamin Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia Exp Neurol 232 2 2011 126 135
74. N. Seeger, C. Zellinger, A. Rode, F. Roloff, G. Bicker, and V. Russmann The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model Epilepsia 52 12 2011 2333 2343
75. G.L. Semenza Hypoxia-inducible factors in physiology and medicine Cell 148 3 2012 399 408
76. N.A. Shein, M. Horowitz, A.G. Alexandrovich, J. Tsenter, and E. Shohami Heat acclimation increases hypoxia-inducible factor 1alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice J Cereb Blood Flow Metab 25 11 2005 1456 1465
77. S. Spaia, M. Pangalos, N. Askepidis, M. Pazarloglou, E. Mavropoulou, and S. Theodoridis Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients Nephron 84 4 2000 320 325
78. S.K. Sreenan, A.A. Mittal, F. Dralyuk, W.L. Pugh, K.S. Polonsky, and M.W. Roe Glucagon-like peptide-1 stimulates insulin secretion by a Ca2 + -independent mechanism in Zucker diabetic fatty rat islets of Langerhans Metabolism 49 12 2000 1579 1587
79. K.H. Su, S.K. Shyue, Y.R. Kou, L.C. Ching, A.N. Chiang, and Y.B. Yu β common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase J Cell Physiol 226 12 2011 3330 3339
80. M. Swartjes, A. Morariu, M. Niesters, M. Brines, A. Cerami, and L. Aarts ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice Anesthesiology 115 5 2011 1084 1092
81. M. Swartjes, M. van Velzen, M. Niesters, L. Aarts, M. Brines, and A. Dunne ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response Mol Pain 10 1 2014 13
82. N. Taniguchi, T. Nakamura, T. Sawada, K. Matsubara, K. Furukawa, and M. Hadase Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study Circ J 74 11 2010 2365 2371
83. C.T. Taylor, and S.P. Colgan Hypoxia and gastrointestinal disease J Mol Med 85 12 2007 1295 1300
84. A. Tuzcu, M. Bahceci, E. Yilmaz, S. Bahceci, and S. Tuzcu The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin Horm Metab Res 36 10 2004 716 720
85. H. Ueba, M. Brines, M. Yamin, T. Umemoto, J. Ako, and S. Momomura Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin Proc Natl Acad Sci U S A 107 32 2010 14357 14362
86. H. Ueba, M. Shiomi, M. Brines, M. Yamin, T. Kobayashi, and J. Ako Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin Mol Med 19 2013 195 202
87. W.G. van Rijt, G.J. Nieuwenhuijs-Moeke, H. van Goor, B. Jespersen, P.J. Ottens, and R.J. Ploeg ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury J Transl Med 11 2013 9
88. J.D. Veldhuis, M.L. Carlson, and M.L. Johnson The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations Proc Natl Acad Sci U S A 84 21 1987 7686 7690
89. A.A. Voors, A.M. Belonje, F. Zijlstra, H.L. Hillege, S.D. Anker, and R.H. Slart A single dose of erythropoietin in ST-elevation myocardial infarction Eur Heart J 31 21 2010 2593 2600
90. S.S. Watowich The erythropoietin receptor: molecular structure and hematopoietic signaling pathways J Investig Med 59 7 2011 1067 1072
91. N. Werth, C. Beerlage, C. Rosenberger, A.S. Yazdi, M. Edelmann, and A. Amr Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens PLoS One 5 7 2010 e11576
92. C. Westenfelder, D.L. Biddle, and R.L. Baranowski Human, rat, and mouse kidney cells express functional erythropoietin receptors Kidney Int 55 3 1999 808 820
93. Y. Wu, J. Zhang, F. Liu, C. Yang, Y. Zhang, and A. Liu Protective effects of HBSP on ischemia reperfusion and cyclosporine a induced renal injury Clin Dev Immunol 2013 2013 758159
94. X. Xu, Z. Cao, B. Cao, J. Li, L. Guo, and L. Que Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism Surgery 146 3 2009 506 514
95. C. Yang, T. Zhao, M. Lin, Z. Zhao, L. Hu, and Y. Jia Helix B surface peptide administered after insult of ischemia reperfusion improved renal function, structure and apoptosis through beta common receptor/erythropoietin receptor and PI3K/Akt pathway in a murine model Exp Biol Med (Maywood) 238 1 2013 111 119
96. A. Zechariah, A. ElAli, and D.M. Hermann Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice Stroke 41 5 2010 1008 1012